DelveInsight’s, “Type 2 Diabetes Pipeline Insight, 2025” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Type 2 Diabetes pipeline landscape. It covers the Type 2 Diabetes pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Type 2 Diabetes pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Type 2 Diabetes Research. Learn more about our innovative pipeline today! @ Type 2 Diabetes Pipeline Outlook
Key Takeaways from the Type 2 Diabetes Pipeline Report
- In July 2025, AstraZeneca announced a Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy.
- In July 2025, Novo Nordisk A/S conducted a study compares insulin icodec, a new insulin taken once a week, to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 2 diabetes. Participants will either get insulin icodec or insulin glargine.
- In July 2025, Sanofi organized a Phase IV Single Arm Clinical Trial to Evaluate the Safety and Efficacy of a Fixed Ratio Combination of Insulin Glargine and Lixisenatide in Adult Patients With Type 2 Diabetes Who Are Sub Optimally Controlled on Oral Anti-hyperglycemic Drugs and/or Basal Insulin/GLP-1 RA.
- In July 2025, Getz Pharma announced a study Objective To evaluate the safety and tolerability of Empagliflozin with or without metformin in patients with Type II Diabetes Mellitus in the Pakistani population.
- DelveInsight’s Type 2 Diabetes pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Type 2 Diabetes treatment.
- The leading Type 2 Diabetes Companies such as Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Rivus Pharmaceuticals, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical and others.
- Promising Type 2 Diabetes Pipeline Therapies such as Empagliflozin, Subetta, AZD6234, AZD1656, Glipizide, iGlarLixi (insulin glargine/lixisenatide), GFT505 80mg, Pioglitazone, Metformin, Sulfonylurea and others.
Stay informed about the cutting-edge advancements in Type 2 Diabetes treatments. Download for updates and be a part of the revolution in Endocrinology and Metabolic Disorders Care @ Type 2 Diabetes Clinical Trials Assessment
Type 2 Diabetes Emerging Drugs Profile
- LY-3209590: Eli Lilly and Company
Insulin efsitora alfa (LY3209590) is a once-weekly basal insulin, a fusion protein that combines a novel single-chain variant of insulin with a human IgG2 Fc domain. It is specifically designed for once-weekly subcutaneous administration, and with its low peak-to-trough ratio, it has the potential to provide more stable glucose levels (less glucose variability) throughout the week. Efsitora is in phase III development for adults with type 1 and 2 diabetes.
- THDB0206: Tonghua Dongbao Pharmaceutical
BC Lispro (THDB0206) is an ultra-rapid-acting insulin analog developed by Tonghua Dongbao Pharmaceutical Co., Ltd. for the treatment of type 2 diabetes. BC Lispro is designed to restore early-phase insulin secretion, which is often impaired in diabetic patients. This insulin analog utilizes a new formulation technology that allows for rapid absorption and action, mimicking the physiological pattern of insulin secretion after meals. Such characteristics are expected to reduce the risk of late postprandial hypoglycemia, providing patients with greater flexibility in managing their insulin injections. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Type 2 Diabetes.
- HU6: Rivus Pharmaceuticals
Rivus Pharmaceuticals is developing HU6, a novel oral medication classified as a Controlled Metabolic Accelerator (CMA), aimed at treating various metabolic diseases, including type 2 diabetes. HU6 works by leveraging mitochondrial uncoupling to increase the body’s resting metabolic rate, promoting fat loss while preserving lean muscle mass. Currently, the drug is in the Phase II stage of development to treat Type 2 Diabetes.
- AZD5004: AstraZeneca
AZD-5004, also known as ECC5004, is an investigational small molecule glucagon-like peptide-1 receptor agonist (GLP-1RA) developed by AstraZeneca in collaboration with Eccogene. It is primarily aimed at treating obesity, type 2 diabetes, and related cardiometabolic conditions. AZD-5004 works by mimicking the effects of GLP-1, a hormone that regulates appetite and insulin secretion. This mechanism is crucial for managing weight and improving glucose metabolism, making it a potential therapeutic option for individuals with obesity and type 2 diabetes. Currently, the drug is in the Phase II stage of development to treat Type 2 Diabetes.
- XW014: Sciwind Biosciences
XW014 is an oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist developed by Sciwind Biosciences for the treatment of obesity and type 2 diabetes (T2D). XW014 functions as a GLP-1 receptor agonist, which means it mimics the action of the GLP-1 hormone that is released after meals. This hormone plays a key role in regulating glucose metabolism by stimulating insulin secretion, inhibiting glucagon release, and promoting satiety. As an oral small molecule, XW014 offers advantages over traditional peptide-based GLP-1 therapies, such as ease of administration and the potential for combination therapies with other oral medications. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Type 2 Diabetes.
- KN056: Suzhou Alphamab Co., Ltd.
KN-056 is a glucagon-like peptide-1 receptor (GLP-1R) modulator developed by Suzhou Alphamab Co., Ltd. for the treatment of type 2 diabetes. KN-056 functions as a GLP-1R modulator, which means it targets the glucagon-like peptide-1 receptor. GLP-1 is a hormone that plays a key role in regulating glucose metabolism by stimulating insulin secretion, inhibiting glucagon release, and promoting satiety. By modulating the GLP-1 receptor, KN-056 aims to improve glycemic control in patients with type 2 diabetes. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Type 2 Diabetes.
The Type 2 Diabetes Pipeline Report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Type 2 Diabetes with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Type 2 Diabetes Treatment.
- Type 2 Diabetes Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Type 2 Diabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Type 2 Diabetes market.
Learn more about Type 2 Diabetes Drugs opportunities in our groundbreaking Type 2 Diabetes research and development projects @ Type 2 Diabetes Unmet Needs
Type 2 Diabetes Companies
Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Rivus Pharmaceuticals, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical and others.
Type 2 Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Type 2 Diabetes Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Discover the latest advancements in Type 2 Diabetes treatment by visiting our website. Stay informed about how we’re transforming the future of Endocrinology and Metabolic Disorders @ Type 2 Diabetes Market Drivers and Barriers, and Future Perspectives
Scope of the Type 2 Diabetes Pipeline Report
- Coverage- Global
- Type 2 Diabetes Companies- Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Rivus Pharmaceuticals, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical and others.
- Type 2 Diabetes Pipeline Therapies- Empagliflozin, Subetta, AZD6234, AZD1656, Glipizide, iGlarLixi (insulin glargine/lixisenatide), GFT505 80mg, Pioglitazone, Metformin, Sulfonylurea and others.
- Type 2 Diabetes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Type 2 Diabetes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Type 2 Diabetes Pipeline on our website @ Type 2 Diabetes Emerging Drugs and Companies
Table of Contents
- Introduction
- Executive Summary
- Type 2 Diabetes: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Type 2 Diabetes– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- LY-3209590: Eli Lilly and Company
- Mid Stage Products (Phase II)
- HU6: Rivus Pharmaceuticals
- Early Stage Products (Phase I)
- KN056: Suzhou Alphamab Co., Ltd.
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Inactive Products
- Type 2 Diabetes Key Companies
- Type 2 Diabetes Key Products
- Type 2 Diabetes- Unmet Needs
- Type 2 Diabetes- Market Drivers and Barriers
- Type 2 Diabetes- Future Perspectives and Conclusion
- Type 2 Diabetes Analyst Views
- Type 2 Diabetes Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/type-2-diabetes-pipeline-insight